Phase I trial: Parexel code: PXL 269850

Phase 1

• Conditions: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.; Not Applicable

• Registration Number: ISRCTN12117857
• Lead Sponsor: MD Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-29
• Last Update Posted: 3 October 2023
• Study Completion: 2024-05-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion Criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Study & Design

• Study Type: Interventional
• Study Design: Not specified